TaurolockTMHep100 Versus Saline 0.9% As Secondary Prevention of Catheter-related Bloodstream Infections (CRBSI); a Single Center, Double Blinded, Randomized, Controlled Study in Patients with Chronic Intestinal Failure Dependent on Home Parenteral Support (HPS)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- Incidence of recurrent catheter-related bloodstream infections
研究概览
简要总结
The purpose of the trial is to compare two catheter lock solutions (active: 1.35% taurolidine and placebo: 0.9% saline), on the occurence of catheter related blood stream infection, in patients with intestinal failure and a central venous catheter for home parenteral support.
详细描述
Patients with long-term intestinal failure rely on Home Parenteral support (HPS) delivered through a central venous catheter(CVC). Catheter Related Blood Stream Infections(CRBSI) are a frequent complication leading to increased morbidity, hospital admissions, cost, and risk of repeated replacement of the CVC. The infections often originate from contamination of the catheter hub, and growth of microorganisms on the inner lumen of the catheter imbedded in a biofilm. To prevent infections good hygiene guidelines and the use of a catheter lock solution is applied.
The primary objective is to compare two catheter lock solutions, 1,35% taurolidine and 0.9% saline, on the occurence of recurrent CRBSIs. The secondary objectives are to compare the two devices according to other catheter-related complications, adverse events and costs.
Patients with at least one prior CRBSI is included. Patients instill the solution in their CVC after each infusion of HPS, with a minimum of three times per week, depending on their individual HPS programme.
Before the blinded randomization the patients will be paired according to age and stratified according to prior CRBSI incidence.
Duration of the instillation will be 24 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients receiving HPS at the department of Medical gastroenterology, Rigshospitalet, who have at least one prior CRBSI and thereby demonstrated susceptibility towards developing CRBSI while on HPS and the following:
- •Signed informed consent form
- •Has a single-lumen subcutaneously tunneled CVC
- •Has been at least 3 weeks since termination of the antibiotic treatment for their last CRBSI
排除标准
- •Patients who:
- •have a known hypersensitivity/allergy to TauroLockTMHep 100 or heparin and/or their excipients
- •are pregnant, lactating or nursing
研究组 & 干预措施
TaurolockTMHep100
干预措施: TaurolockTMHep100 (Device)
0.9% saline
干预措施: 0.9 % saline (Device)
结局指标
主要结局
Incidence of recurrent catheter-related bloodstream infections
时间窗: Treatment time 2 years
次要结局
未报告次要终点
研究者
Palle Bekker Jeppesen
MD, PhD, DMSc, Professor
Rigshospitalet, Denmark
